Xenon Pharma CMO sells 7,068 shares at ~$61

Xenon Pharmaceuticals Inc. (XENE) reported that Chief Medical Officer Christopher John Kenney sold a total of 7,068 Common Shares on August 28, 2026 in two open-market transactions, executed under a Rule 10b5-1 trading plan adopted on May 29, 2026.

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. (XENE) reported that Chief Medical Officer Christopher John Kenney sold a total of 7,068 Common Shares on August 28, 2026 in two open-market transactions, executed under a Rule 10b5-1 trading plan adopted on May 29, 2026. The reported prices are weighted-average prices for multiple trades within specified intraday ranges.

Insider Trade Summary 10b5-1

Net Seller: 7,068 shares

Net Sell 2 txns

Insider KENNEY CHRISTOPHER JOHN

Role Chief Medical Officer

Sold 7,068 shs ($426K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F2	6,368	$60.1673	$383K
Sale	Common Shares F1, F3, F4	700	$60.9766	$43K

Holdings After Transaction: Common Shares — 2 shares (Direct)

Footnotes (4)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.
2. F2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
3. F3. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
4. F4. The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4.

Key Figures

Total shares sold: 7,068 Common Shares First sale shares: 6,368 Common Shares First sale weighted-average price: $60.1673 per share +4 more

7 metrics

Total shares sold 7,068 Common Shares Aggregate non-derivative sales on August 28, 2026

First sale shares 6,368 Common Shares Non-derivative sale on August 28, 2026

First sale weighted-average price $60.1673 per share Weighted-average price; individual trades between $59.79 and $60.68

Second sale shares 700 Common Shares Non-derivative sale on August 28, 2026

Second sale weighted-average price $60.9766 per share Weighted-average price; individual trades between $60.81 and $61.12

Net shares sold 7,068 shares Net buy/sell shares across all reported transactions in this Form 4

Rule 10b5-1 plan adoption date May 29, 2026 Date the reporting person adopted the trading plan used for these sales

Key Terms

Rule 10b5-1 trading plan, weighted-average price, beneficially owned, non-derivative

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The "Amount" and "Price" ... reflect the aggregate number and weighted-average price"

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

beneficially owned financial

"The number of shares beneficially owned following the reported transactions"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

non-derivative financial

"transaction_type": "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider trading Xenon Pharmaceuticals (XENE) shares in this Form 4?

The insider is Christopher John Kenney, who serves as Chief Medical Officer of Xenon Pharmaceuticals Inc. He is an officer but not listed as a director or ten percent owner in this filing.

How many Xenon Pharmaceuticals (XENE) shares did the CMO sell on August 28, 2026?

On August 28, 2026, the Chief Medical Officer sold an aggregate of 7,068 Common Shares of Xenon Pharmaceuticals Inc., reported across two separate open-market sale transactions.

At what prices were the Xenon Pharmaceuticals (XENE) shares sold in this Form 4?

One sale of 6,368 shares had a weighted-average price of $60.17, with individual trades between $59.79 and $60.68. Another sale of 700 shares had a weighted-average price of $60.98, with trades between $60.81 and $61.12.

Were the Xenon Pharmaceuticals (XENE) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026, and the Rule 10b5-1 checkbox for the filing is affirmed.

Does this Xenon Pharmaceuticals (XENE) Form 4 show the insider’s remaining share holdings?

The filing notes that the number of shares beneficially owned after the reported transactions reflects an upward adjustment of one share from a prior Form 4, but it does not state a specific total shares figure in the structured data.

How many sell transactions are reported for Xenon Pharmaceuticals (XENE) in this Form 4?

The Form 4 reports two non-derivative sale transactions in Xenon Pharmaceuticals Inc. Common Shares, both on August 28, 2026, for a combined total of 7,068 shares sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 10:00 PM EDT Accepted by SEC EDGAR 08/31/2026 - 09:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KENNEY CHRISTOPHER JOHN

(Last) (First) (Middle)

3650 GILMORE WAY

(Street)

BURNABY V5G 4W8

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/28/2026		S(1)		6,368	D	$60.1673(2)	702	D
Common Shares	08/28/2026		S(1)		700	D	$60.9766(3)	2(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.

2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

4. The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4.

	/s/ Nathaniel Adams, Attorney-in-fact	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)